Algorae Pharmaceuticals Limited · ASX:1AI
David Hainsworth received 30,000,003 Algorae Pharmaceuticals Limited shares as an award (Appendix 3Y, ASX)
Traded Nov 11, 2026 · Filed Nov 11, 2026
On Nov 11, 2026, David Hainsworth (Director) received 30,000,003 Algorae Pharmaceuticals Limited shares as an award. Filed Nov 11, 2026 (Appendix 3Y, ASX).
- Awarded
- 30,000,003 shares
- Role
- Director
The filing in full
Appendix 3Y
*Rule 3.19A.2*
Change of Director’s Interest Notice
*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Algorae Pharmaceuticals Limited (ASX:1AI) |
|---|---|
| ABN | 14 104 028 042 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
| Name of Director | David Hainsworth |
|---|---|
| Date of last notice | 30 September 2026 |
Part 1 - Change of director’s relevant interests in securities
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Direct or indirect interest | Indirect 1 |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Indirect 1 Union Square Capital Pty Ltd Indirect 2 Cathedral Estate Pty Ltd |
| Date of change | 11 November 2026 |
- See chapter 19 for defined terms.
---
| No. of securities held prior to change | Direct (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 1 Union Square Capital Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) Nil Indirect 2 Cathedral Estate Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. |
|---|---|
| Class | Performance Rights |
| Number acquired | Indirect 1 30,000,000 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil |
- See chapter 19 for defined terms.
---
| No. of securities held after change | Direct (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 1 Union Square Capital Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 30,000,000 performance rights (AGM 2026). Indirect 2 Cathedral Estate Pty Ltd , an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. |
|---|---|
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026. |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
---
Appendix 3Y
Change of Director’s Interest Notice
| Interest acquired | N/A |
|---|---|
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
+
Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
---
Appendix 3Y
*Rule 3.19A.2*
Change of Director’s Interest Notice
*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Algorae Pharmaceuticals Limited (ASX:1AI) |
|---|---|
| ABN | 14 104 028 042 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
| Name of Director | David Gulland |
|---|---|
| Date of last notice | 12 March 2026 |
Part 1 - Change of director’s relevant interests in securities
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Direct or indirect interest | Indirect 2 |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Indirect 1 Mrs Rachelle Gulland Indirect 2 Gull Health Pty Ltd |
| Date of change | 11 November 2026 |
- See chapter 19 for defined terms.
---
| No. of securities held prior to change | Indirect 1 Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Gull Health Pty Ltd , an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; and (c) 42,000,000 performance rights. |
|---|---|
| Class | Performance Rights |
| Number acquired | Indirect 2 30,000,000 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil |
| No. of securities held after change | Indirect 1 Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Gull Health Pty Ltd , an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; (c) 42,000,000 performance rights; and (d) 30,000,000 performance rights (2026 AGM). |
---
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backIssue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
+
Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
---
Appendix 3Y
*Rule 3.19A.2*
Change of Director’s Interest Notice
*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Algorae Pharmaceuticals Limited (ASX:1AI) |
|---|---|
| ABN | 14 104 028 042 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
| Name of Director | Troy Valentine |
|---|---|
| Date of last notice | 21 July 2026 |
Part 1 - Change of director’s relevant interests in securities
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Direct or indirect interest | Direct |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Indirect 1 Valplan Pty Ltd Indirect 2 Citieside Investments Pty Ltd Indirect 3 Alignment Capital Pty Ltd |
| Date of change | 11 November 2026 |
- See chapter 19 for defined terms.
---
| No. of securities held prior to change | Direct (a) Nil. Indirect 1 Valplan Pty Ltd , an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 3 Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. |
|---|---|
| Class | Performance Rights |
| Number acquired | Direct 30,000,000 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Nil |
- See chapter 19 for defined terms.
---
| No. of securities held after change | Direct (a) 30,000,000 performance rights (2026 AGM). Indirect 1 Valplan Pty Ltd , an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 2 Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. Indirect 3 Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. |
|---|---|
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026. |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
- See chapter 19 for defined terms.
---
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
|---|---|
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
+ Part 3 – Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Performance Rights | Award | 1 | |||
| Nov 11, 2026 | Performance Rights | Award | 2 | |||
| Nov 11, 2026 | Performance Rights | Award | 30,000,000 |
Source
Download PDF · View original at ASX